Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Oncology & Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NAMPT/PBEF drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NAMPT/PBEF Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View NAMPT/PBEF Products |
| Gene Delivery | NAMPT/PBEF Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High titer (>10^8 TU/ml). |
View NAMPT/PBEF Products |
| Benchmark Ab | Anti-NAMPT/PBEF (Research Grade) Recombinant monoclonal for ELISA/WB validation. |
View NAMPT/PBEF Products |
| Validator | NAMPT/PBEF siRNA Set For knockdown verification and specificity controls. |
View NAMPT/PBEF Products |
| Related Target A | NMNAT1 Downstream NAD+ synthesis enzyme (synthetic lethality partner) |
View NMNAT1 Products |
| Related Target B | PARP1 NAD+ consumption pathway partner (combination therapy target) |
View PARP1 Products |
| Related Target C | NAPRT Alternative NAD+ salvage pathway enzyme; critical for synthetic lethality rescue assays. |
View NAPRT Products |
| Related Target D | SIRT1 Downstream NAD+-dependent deacetylase; key biomarker for NAMPT inhibition efficacy. |
View SIRT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-Throughput Enzyme Screening (Active site conformation) | High-purity (>95%) active enzyme dimer confirmed by SEC-HPLC; Theoretical MW verified; verified by mass spectrometry. |
| Cross-species cyno/mouse eval for toxicity | Human/Mouse/Cyno ortholog proteins available with >95% purity; Sequence Verified. |
| Target Engagement & Control Validation | Validated siRNA included for specificity checks; Lentivirus for rescue experiments; clinical benchmark antibodies provided for reliable calibration. |
| Off-target Panel (NMNAT selectivity) | Homolog panel proteins (NMNAT1/2/3) strictly verified by mass spec for counter-screening. |
| Differentiating eNAMPT vs iNAMPT | Sequence-verified structural fidelity to ensure accurate epitope recognition for extracellular targeting. |
| False Positive & Non-specificity Reduction | Validated siRNA and benchmark antibodies included to minimize false positives in efficacy assays. |
Live NAMPT/PBEF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NAMPT/PBEF therapeutics is intensifying. First-generation small molecule inhibitors (e.g., FK866, CHS-828) demonstrated potent anti-tumor activity by starving cancer cells of NAD+, but faced dose-limiting toxicities (thrombocytopenia, retinal toxicity, cardiovascular events), stalling initial clinical progress. The next wave of R&D is shifting toward precision oncology paradigms — specifically targeting tumors deficient in the NAPRT rescue pathway (synthetic lethality), thereby expanding the therapeutic window. Innovative modalities include allosteric modulators for inflammatory diseases, PROTAC-mediated degradation for refractory cancers, and monoclonal antibodies targeting extracellular NAMPT (eNAMPT/PBEF) for severe inflammation (e.g., ARDS). Combination strategies with PARP inhibitors in BRCA-mutant cancers are also under active investigation. Notably, a somatic mutation of NAMPT has been documented in a colorectal cancer sample (UniProt P43490 VAR-036614), suggesting potential for personalized targeting.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Karyopharm, OncoTartis, Chelate Pharma, AstraZeneca | Solid Tumors, Hematological Malignancies | Enzymatic Activity Assay (Need high-purity active enzyme) |
| Allosteric Modulator | Emerging Biotechs | Inflammatory Diseases | Conformational Binding Assay (Need full-length native protein) |
| PROTACs | Preclinical Biotech | Refractory Cancers | Degradation Validation (Need benchmark Abs and Lentivirus for cell lines) |
| Monoclonal Antibodies | Aqualung Therapeutics | ARDS, Severe Inflammation | Binding / Neutralization Assay (Need extracellular antigen / target ECD) |
| Combination (PARPi) | Oncology Institutes | BRCA-mutant Cancers | Cellular NAD+ Depletion Assay (Need Lentivirus for stable lines) |